FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma

RECURSION PHARMACEUTICALS, INC.

FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
Phase 1/2 trial to start Q4 2024 evaluating safety, tolerability, PK/PD, and monotherapy efficacy.
Target identified via Recursion's AI platform; program advanced from target to IND in under 18 months.
Initially addressable population estimated at >100,000 patients in the US and EU5.
Preclinical data show RBM39 degradation induces splicing defects downregulating DNA Damage Response networks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.